ストックスクリーナーアプリを入手
1.02
0.99%
0.01
アフターアワーズ：
1.02
前日終値:
$1.01
開ける：
$1
24時間の取引高:
91,885
Relative Volume:
0.21
時価総額：
$113.91M
収益：
-
当期純損益:
$-21.65M
株価収益率:
-3.0714
EPS:
-0.3321
ネットキャッシュフロー:
$-15.84M
1週間 パフォーマンス:
-0.97%
1か月 パフォーマンス:
+0.99%
6か月 パフォーマンス:
-8.11%
1年 パフォーマンス:
-9.73%
1日の値動き範囲:
$1.00
$1.04
1週間の範囲:
$0.9803
$1.07
52週間の値動き範囲:
$0.7709
$1.59
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.02 | 112.80M | 0 | -21.65M | -15.84M | -0.3321 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-26 | 開始されました | ROTH MKM | Buy |
| 2024-04-22 | 開始されました | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc (CRDL) 最新ニュース
CRDL: Pivotal phase 3 data for CardiolRx in pericarditis expected late 2024, supporting broad expansion - TradingView
Cardiol Therapeutics (NASDAQ:CRDL) Shares Down 1%What's Next? - MarketBeat
Immix Biopharma to Participate in Upcoming Investor Conferences - Investing News Network
Aug Highlights: Should you avoid Cardiol Therapeutics Inc stock right nowPortfolio Performance Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Cardiol Therapeutics (TSE:CRDL) Trading Down 4.8%Time to Sell? - MarketBeat
Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference - TipRanks
Cardiol Therapeutics (NASDAQ: CRDL) outlines heart programs at TD Cowen - Stock Titan
Heart disease-focused Cardiol to present at TD Cowen conference - Stock Titan
Objective long/short (CRDL) Report (CRDL:CA) - Stock Traders Daily
argenx to Present at TD Cowen 46th Annual Healthcare Conference - Investing News Network
Should I trade or invest in Cardiol Therapeutics Inc.Market Activity Summary & High Conviction Trade Alerts - mfd.ru
CRDLCardiol Therapeu Latest Stock News & Market Updates - Stock Titan
(CRDL) Trading Performance and Risk Management (CRDL:CA) - Stock Traders Daily
Is Cardiol Therapeutics Inc. (CT9) stock a contrarian opportunityWeekly Trade Summary & Long-Term Safe Investment Ideas - mfd.ru
Moderna to Present at Upcoming Conferences in March 2026 - Investing News Network
Learn to Evaluate (CRDL) using the Charts (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics announces $13.5M bought-deal private placement - MSN
Trend Report: Is Cardiol Therapeutics Inc a cyclical or defensive stockExit Point & Reliable Price Breakout Signals - baoquankhu1.vn
(CRDL) Trading Signals (CRDL:CA) - Stock Traders Daily
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 - Investing News Network
Aug Drivers: Is Cardiol Therapeutics Inc stock risky to hold nowRecession Risk & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Why Cardiol Therapeutics Inc. stock remains resilientWeekly Investment Summary & AI Driven Stock Price Forecasts - mfd.ru
Is Cardiol Therapeutics Inc. a momentum stockWeekly Profit Report & Safe Capital Growth Plans - mfd.ru
(CRDL) Financial Trading Report (CRDL:CA) - Stock Traders Daily
Published on: 2026-02-16 14:51:25 - baoquankhu1.vn
Can Cardiol Therapeutics Inc generate free cash flow2025 Price Action Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and Centene (CNC) - The Globe and Mail
Cardiol Therapeutics publishes phase II myocarditis study results By Investing.com - Investing.com Nigeria
CRDL Stock Rating Reiterated at 'Buy' by HC Wainwright & Co. | C - GuruFocus
Cardiol Therapeutics (NASDAQ:CRDL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics publishes phase II myocarditis study results - Investing.com
Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure - TipRanks
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure - Investing News Network
How the (CRDL) price action is used to our Advantage (CRDL:CA) - Stock Traders Daily
Equities Analysts Set Expectations for CRDL FY2025 Earnings - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Stock Rating Upgraded by Brookline Cap M - MarketBeat
Analysts Offer Predictions for CRDL FY2025 Earnings - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell? - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1%Time to Sell? - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Upgraded at Brookline Capital Management - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at Brookline Capital Management - MarketBeat
(CRDL) Market Dynamics and Trading Signals (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics files underwriting agreement and warrant indenture By Investing.com - Investing.com Nigeria
Cardiol Therapeutics files underwriting agreement and warrant indenture - Investing.com
Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing - TipRanks
Targets Report: Can Cardiol Therapeutics Inc weather a recessionPortfolio Profit Report & Daily Growth Stock Tips - baoquankhu1.vn
Fund Flows: Will Ambarella Inc stock benefit from M A2025 Trading Volume Trends & Safe Swing Trade Setups - baoquankhu1.vn
Aug Retail: Is MPWR in a bullish channel2025 Volatility Report & Daily Entry Point Trade Alerts - baoquankhu1.vn
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic - Investing News Network
(CRDL) Strategic Equity Report (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics Inc (CRDL) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):